Anti-myelin-associated glycoprotein antibodies predict the development of neuropathy in asymptomatic patients with IgM monoclonal gammopathy

N. Meucci, L. Baldini, A. Cappellari, A. Di Troia, S. Allaria, G. Scarlato, E. Nobile-Orazio

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

We examined 52 asymptomatic patients with IgM monoclonal gammopathy and correlated anti-myelin-associated glycoprotein (anti-MAG) IgM with the presence of subclinical neuropathy and, in 24 of these patients, with the development of symptomatic neuropathy during a follow-up interval of 40 to 144 months (mean, 75.3 months). Three of 6 patients (50%) with high (> 1/6,400) anti-MAG IgM had subclinical neuropathy at entry compared with 2 of 46 patients (4.3%) with low or no reactivity. At follow-up, a symptomatic neuropathy occurred in 3 of 4 patients with high reactivity and in 3 of 21 patients with low or no reactivity. The correlation of high anti-MAG IgM with the presence of subclinical neuropathy or the development of symptomatic neuropathy supports its pathogenetic role in the neuropathy.

Original languageEnglish
Pages (from-to)119-122
Number of pages4
JournalAnnals of Neurology
Volume46
Issue number1
DOIs
Publication statusPublished - 1999

Fingerprint

Myelin-Associated Glycoprotein
Paraproteinemias
Immunoglobulin M
Antibodies

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Anti-myelin-associated glycoprotein antibodies predict the development of neuropathy in asymptomatic patients with IgM monoclonal gammopathy. / Meucci, N.; Baldini, L.; Cappellari, A.; Di Troia, A.; Allaria, S.; Scarlato, G.; Nobile-Orazio, E.

In: Annals of Neurology, Vol. 46, No. 1, 1999, p. 119-122.

Research output: Contribution to journalArticle

@article{f85b0db0ff27412ca6b6353598a7c74a,
title = "Anti-myelin-associated glycoprotein antibodies predict the development of neuropathy in asymptomatic patients with IgM monoclonal gammopathy",
abstract = "We examined 52 asymptomatic patients with IgM monoclonal gammopathy and correlated anti-myelin-associated glycoprotein (anti-MAG) IgM with the presence of subclinical neuropathy and, in 24 of these patients, with the development of symptomatic neuropathy during a follow-up interval of 40 to 144 months (mean, 75.3 months). Three of 6 patients (50{\%}) with high (> 1/6,400) anti-MAG IgM had subclinical neuropathy at entry compared with 2 of 46 patients (4.3{\%}) with low or no reactivity. At follow-up, a symptomatic neuropathy occurred in 3 of 4 patients with high reactivity and in 3 of 21 patients with low or no reactivity. The correlation of high anti-MAG IgM with the presence of subclinical neuropathy or the development of symptomatic neuropathy supports its pathogenetic role in the neuropathy.",
author = "N. Meucci and L. Baldini and A. Cappellari and {Di Troia}, A. and S. Allaria and G. Scarlato and E. Nobile-Orazio",
year = "1999",
doi = "10.1002/1531-8249(199907)46:1<119::AID-ANA18>3.0.CO;2-H",
language = "English",
volume = "46",
pages = "119--122",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Anti-myelin-associated glycoprotein antibodies predict the development of neuropathy in asymptomatic patients with IgM monoclonal gammopathy

AU - Meucci, N.

AU - Baldini, L.

AU - Cappellari, A.

AU - Di Troia, A.

AU - Allaria, S.

AU - Scarlato, G.

AU - Nobile-Orazio, E.

PY - 1999

Y1 - 1999

N2 - We examined 52 asymptomatic patients with IgM monoclonal gammopathy and correlated anti-myelin-associated glycoprotein (anti-MAG) IgM with the presence of subclinical neuropathy and, in 24 of these patients, with the development of symptomatic neuropathy during a follow-up interval of 40 to 144 months (mean, 75.3 months). Three of 6 patients (50%) with high (> 1/6,400) anti-MAG IgM had subclinical neuropathy at entry compared with 2 of 46 patients (4.3%) with low or no reactivity. At follow-up, a symptomatic neuropathy occurred in 3 of 4 patients with high reactivity and in 3 of 21 patients with low or no reactivity. The correlation of high anti-MAG IgM with the presence of subclinical neuropathy or the development of symptomatic neuropathy supports its pathogenetic role in the neuropathy.

AB - We examined 52 asymptomatic patients with IgM monoclonal gammopathy and correlated anti-myelin-associated glycoprotein (anti-MAG) IgM with the presence of subclinical neuropathy and, in 24 of these patients, with the development of symptomatic neuropathy during a follow-up interval of 40 to 144 months (mean, 75.3 months). Three of 6 patients (50%) with high (> 1/6,400) anti-MAG IgM had subclinical neuropathy at entry compared with 2 of 46 patients (4.3%) with low or no reactivity. At follow-up, a symptomatic neuropathy occurred in 3 of 4 patients with high reactivity and in 3 of 21 patients with low or no reactivity. The correlation of high anti-MAG IgM with the presence of subclinical neuropathy or the development of symptomatic neuropathy supports its pathogenetic role in the neuropathy.

UR - http://www.scopus.com/inward/record.url?scp=0033010768&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033010768&partnerID=8YFLogxK

U2 - 10.1002/1531-8249(199907)46:1<119::AID-ANA18>3.0.CO;2-H

DO - 10.1002/1531-8249(199907)46:1<119::AID-ANA18>3.0.CO;2-H

M3 - Article

VL - 46

SP - 119

EP - 122

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 1

ER -